Eliminating hepatitis C: Part 3. Curing hepatitis C in general practice

Tara Purcell; Amanda Wade; Lisa Accadia; Simone Strasser; Phillip Read; Nicole Allard; David Baker; Alisa Pedrana; Joseph Doyle

Eliminating hepatitis C: Part 3. Curing hepatitis C in general practice

Tara Purcell, Amanda Wade, Lisa Accadia, Simone Strasser, Phillip Read, Nicole Allard, David Baker, Alisa Pedrana, Joseph Doyle

Research output: Contribution to journal › Review Article › Other › peer-review

2 Citations (Scopus)

Abstract

Most patients with hepatitis C are treated with pangenotypic direct-acting antivirals (DAAs) such as sofosbuvir/velpatasvir and glecaprevir/pibrentasvir. GPs experienced in the management of hepatitis C can prescribe DAAs independently. Others must consult with a specialist before prescribing; online resources can streamline this process. Important considerations before prescribing include barriers to adherence and drug interactions.

Original language	English
Pages (from-to)	20-26
Number of pages	7
Journal	Medicine Today
Volume	20
Issue number	8
Publication status	Published - 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{da72246d67194f06b8e56022d4ab03b4,

title = "Eliminating hepatitis C: Part 3. Curing hepatitis C in general practice",

abstract = "Most patients with hepatitis C are treated with pangenotypic direct-acting antivirals (DAAs) such as sofosbuvir/velpatasvir and glecaprevir/pibrentasvir. GPs experienced in the management of hepatitis C can prescribe DAAs independently. Others must consult with a specialist before prescribing; online resources can streamline this process. Important considerations before prescribing include barriers to adherence and drug interactions.",

author = "Tara Purcell and Amanda Wade and Lisa Accadia and Simone Strasser and Phillip Read and Nicole Allard and David Baker and Alisa Pedrana and Joseph Doyle",

year = "2019",

language = "English",

volume = "20",

pages = "20--26",

journal = "Medicine Today",

issn = "1443-430X",

publisher = "Medicine Today Pty Ltd",

number = "8",

}

TY - JOUR

T1 - Eliminating hepatitis C

T2 - Part 3. Curing hepatitis C in general practice

AU - Purcell, Tara

AU - Wade, Amanda

AU - Accadia, Lisa

AU - Strasser, Simone

AU - Read, Phillip

AU - Allard, Nicole

AU - Baker, David

AU - Pedrana, Alisa

AU - Doyle, Joseph

PY - 2019

Y1 - 2019

N2 - Most patients with hepatitis C are treated with pangenotypic direct-acting antivirals (DAAs) such as sofosbuvir/velpatasvir and glecaprevir/pibrentasvir. GPs experienced in the management of hepatitis C can prescribe DAAs independently. Others must consult with a specialist before prescribing; online resources can streamline this process. Important considerations before prescribing include barriers to adherence and drug interactions.

AB - Most patients with hepatitis C are treated with pangenotypic direct-acting antivirals (DAAs) such as sofosbuvir/velpatasvir and glecaprevir/pibrentasvir. GPs experienced in the management of hepatitis C can prescribe DAAs independently. Others must consult with a specialist before prescribing; online resources can streamline this process. Important considerations before prescribing include barriers to adherence and drug interactions.

UR - http://www.scopus.com/inward/record.url?scp=85071693987&partnerID=8YFLogxK

M3 - Review Article

AN - SCOPUS:85071693987

SN - 1443-430X

VL - 20

SP - 20

EP - 26

JO - Medicine Today

JF - Medicine Today

IS - 8

ER -

Eliminating hepatitis C: Part 3. Curing hepatitis C in general practice

Abstract

UN SDGs

Other files and links

Cite this